ARTICLE | Company News
CYPB, Pierre Fabre in neurological deal
August 1, 2001 7:00 AM UTC
Cypress Bioscience (CYPB) received an exclusive license from Pierre Fabre Medicament to develop and market any product with milnacipran, a modulator of the neurotransmitters serotonin and noradrenalin...